About Aevi Genomic Medicine
Aevi Genomic Medicine is a Healthcare company based in Wayne (United States) founded in 2001, and was acquired by Cerecor in December 2019. Therapeutics for rare diseases in neurology and hematology are developed. Aevi Genomic Medicine has raised $28.43 million across 12 funding rounds from investors including Children's Hospital of Philadelphia, Cerecor and Alta Partners. The company has 3 employees. Its chief executive, as recorded, is Mike Cola. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is AEVI GENOMIC MEDICINE, INC. Its competitors include Moderna, BridgeBio and BeiGene; 3 of its 3 listed competitors have raised funding.
Company details
Aevi Genomic Medicine was founded in 2001 and is based in Wayne, United States. Operations center on the creation of treatments for pediatric-onset rare diseases, with emphasis on neurology and hematology sectors. The pipeline encompasses AEVI-001, a small molecule addressing metabotropic glutamate receptor mutations for ADHD and 22q deletion syndrome in Phase 1 and 2 trials, alongside AEVI-002, an anti-LIGHT monoclonal antibody for inflammatory bowel disease in Phase 1.
- Headquarters Wayne, United States
- Employees 3
- Stage Acquired
- SectorsHealthcare
- Website aevigenomics.com
- Social X
- Acquired by Cerecor (Dec 2019)
- Legal Name Aevi Genomic Medicine, Inc.
- Net Profit-$30.78 M (USD)11as on Dec 31, 2018
- EBITDA-$30.96 M (USD)11as on Dec 31, 2018
- Total Equity Funding$28.43M (USD)
in 12 rounds
- Latest Funding Round$28M (USD), Post-IPO
Aug 2017
- InvestorsChildren's Hospital of Philadelphia
& 4 more
- Employee Count3
- Acquired byCerecor
(Dec 2019)
Funding Insights of Aevi Genomic Medicine
Aevi Genomic Medicine has successfully raised a total of $28.43M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $28 million completed in August 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.43M
- Total Rounds 12
- Last Round Post-IPO β $28M
- First Round $7M
(Jun 2001)
- Investors Count 4
Latest 10 of 12 funding rounds of Aevi Genomic Medicine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2017 | $28M | Post-IPO | β | β | |
| Oct 2015 | $3.2M | Post-IPO | β | β | β |
| Jun 2015 | $3.4M | Grant | β | β | β |
| Nov 2014 | $21M | Private Equity Round | β | β | β |
| Apr 2014 | $2.2M | Grant | β | β | β |
| Jul 2013 | $1.9M | Grant | β | β | β |
| Jul 2012 | $9.53M | Post-IPO | β | β | β |
| May 2012 | $2.2M | Grant | β | β | β |
| Nov 2010 | $4M | Debt – Conventional | β | β | β |
| May 2010 | $430,370 | Seed | β | β | β |
5 investors in total: 5 institutional.
Investors in Aevi Genomic Medicine
Aevi Genomic Medicine has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Children's Hospital of Philadelphia, Cerecor and Alta Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
| koor.co.il | ||||
VC firm investing in Western Europe, the US and Israel | altaberkeley.com | London, United Kingdom | ||
Chain of pediatrics hospitals | 1855 | chop.edu | United States | |
Therapeutics for immunological and neurological disorders are developed. | 2011 | cerecor.com | Baltimore, United States |
Investor details for Aevi Genomic Medicine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aevi Genomic Medicine
4 people are tracked at Aevi Genomic Medicine (4 in leadership); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Mike Cola | CEO | Leadership |
Michael F. Cola | President & CEO | Leadership |
Michael H. Mcinaw | Chief Financial Officer | Leadership |
Garry A. Neil | Chief Scientific Officer | Leadership |
Complete people profiles for Aevi Genomic Medicine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aevi Genomic Medicine
5 dated milestones of Aevi Genomic Medicine across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Aevi Genomic Medicine is founded.
- Funding First funding round of $7.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $28.0M.
- Exit Acquired by Cerecor.
Competitors of Aevi Genomic Medicine
Aevi Genomic Medicine has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed competitors of Aevi Genomic Medicine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Aevi Genomic Medicine (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aevi Genomic Medicine
Complete news archive for Aevi Genomic Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aevi Genomic Medicine
Aevi Genomic Medicine was founded in 2001.
Aevi Genomic Medicine is headquartered in Wayne, United States.
Mike Cola is the CEO of Aevi Genomic Medicine, as recorded in our data.
Aevi Genomic Medicine is a funded company, having raised a total of $28.43M across 12 funding rounds to date. The company's 1st funding round was a Seed of $430.37K, raised on Jun 2001.
Aevi Genomic Medicine has 3 employees.
Aevi Genomic Medicine was founded in 2001 and is based in Wayne, United States. Operations center on the creation of treatments for pediatric-onset rare diseases, with emphasis on neurology and hematology sectors. The pipeline encompasses AEVI-001, a small molecule addressing metabotropic glutamate receptor mutations for ADHD and 22q deletion syndrome in Phase 1 and 2 trials, alongside AEVI-002, an anti-LIGHT monoclonal antibody for inflammatory bowel disease in Phase 1.
Aevi Genomic Medicine has 5 investors. Key investors include Children's Hospital of Philadelphia, Cerecor, Alta Partners, Koor Industries, and Alta Berkeley.
Aevi Genomic Medicine operates through Aevi Genomic Medicine, Inc..
Yes. Aevi Genomic Medicine was acquired by Cerecor in December 2019.

